The target Population
for traditional Chinese medicine is expected to account for 56% of the total
treated osteoporotic patients in the year 2017. Rising disposable income,
increasing awareness and preference among consumers to go the traditional way
would drive this growth.
The Osteoporosis Drug Market in China in China reached a
market size of USD 1,608.9 million in the year 2012 with the growing number of
osteoporotic patients in the country. The number of osteoporotic patients in
China was registered at 73.6 million in 2012. Majority of the growth in the
osteoporotic drug segment has been driven by the traditional Chinese medicine
which has steered the overall growth of this market by growing at a CAGR of
6.7% during 2007-2017. In the coming years this segment is further expected to
propel and register a CAGR of 9.7% during 2012-2017. Xianling Gubao is a
leading traditional Chinese medicine used for treatment of osteoporosis in
China. High demand of traditional medicine can be attributed to the majority of
the population in China residing in smaller towns and cities. Moreover high
affordability and convenient availability have also significantly driven the
growth of traditional medicine in the country. Additionally people in even
urban areas now prefer to go the traditional way. For instance a significant
portion of the revenues of Xianling Gubao in China comes from the leading
hospitals in the country. These factors would continue to contribute to the
growing drug market for osteoporosis in the country.
“High consumption and
demand of traditional Chinese medicine Xianling Gubao has also been made a part
of the reimbursement list in the state health insurance of China.”-
According to the research report ‘China Osteoporosis Market Outlook to 2017– Traditional
Chinese Medicine to Steer the Growth’ from Ken Research.
According to the report, market for the
China Osteoporosis Market would be majorly driven by the growing osteoporosis
patients in the country while the drug market would be dominated by the high
demand for traditional Chinese medicine.
The report
provides detailed overview on the osteoporosis market in China and aids
readers to identify the ongoing trends in the industry and anticipated growth
in future depending upon changing industry dynamics in coming years. The report
will help industry consultants, osteoporosis drug companies, diagnostic service
providers, diagnosis equipment manufacturers and other stakeholders to align
their market centric strategies according to ongoing and expected trends in
future.
For more information on
the industry research report please refer to the below mentioned link:
No comments:
Post a Comment